Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment
Xi Wang,Shu-Sen Wang,Heng Huang,Li Cai,Li Zhao,Rou-Jun Peng,Ying Lin,Jun Tang,Jian Zeng,Le-Hong Zhang,Yong-Li Ke,Xian-Ming Wang,Xin-Mei Liu,Qian-Jun Chen,An-Qin Zhang,Fei Xu,Xi-Wen Bi,Jia-Jia Huang,Ji-Bin Li,Dan-Mei Pang,Cong Xue,Yan-Xia Shi,Zhen-Yu He,Huan-Xin Lin,Xin An,Wen Xia,Ye Cao,Ying Guo,Yan-Hong Su,Xin Hua,Xin-Yue Wang,Ruo-Xi Hong,Kui-Kui Jiang,Chen-Ge Song,Zhang-Zan Huang,Wei Shi,Yong-Yi Zhong,Zhong-Yu Yuan,,
DOI: https://doi.org/10.1001/jama.2020.23370
IF: 11.816
2021-01-05
JAMA
Abstract:<span><strong>Question</strong> <span>Does therapy with low-dose capecitabine maintenance after standard adjuvant chemotherapy reduce the risk of relapse and death in early-stage triple-negative breast cancer?</span><strong>Findings</strong> <span>In this randomized clinical trial of 434 women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year, compared with observation, resulted in significantly higher 5-year disease-free survival (82.8% vs 73.0%; hazard ratio for risk of recurrence or death, 0.64).</span><strong>Meaning</strong> <span>Among women with early-stage triple-negative breast cancer, maintenance therapy with low-dose capecitabine significantly improved disease-free survival at 5 years.</span><strong>Importance</strong> <span>Among all subtypes of breast cancer, triple-negative breast cancer has a relatively high relapse rate and poor outcome after standard treatment. Effective strategies to reduce the risk of relapse and death are needed.</span><strong>Objective</strong> <span>To evaluate the efficacy and adverse effects of low-dose capecitabine maintenance after standard adjuvant chemotherapy in early-stage triple-negative breast cancer.</span><strong>Design, Setting, and Participants</strong> <span>Randomized clinical trial conducted at 13 academic centers and clinical sites in China from April 2010 to December 2016 and final date of follow-up was April 30, 2020. Patients (n = 443) had early-stage triple-negative breast cancer and had completed standard adjuvant chemotherapy.</span><strong>Interventions</strong> <span>Eligible patients were randomized 1:1 to receive capecitabine (n = 222) at a dose of 650 mg/m<sup>2</sup> twice a day by mouth for 1 year without interruption or to observation (n = 221) after completion of standard adjuvant chemotherapy.</span><strong>Main Outcomes and Measures</strong> <span>The primary end point was disease-free survival. Secondary end points included distant disease-free survival, overall survival, locoregional recurrence-free survival, and adverse events.</span><strong>Results</strong> <span>Among 443 women who were randomized, 434 were included in the full analysis set (mean [SD] age, 46 [9.9] years; T1/T2 stage, 93.1%; node-negative, 61.8%) (98.0% completed the trial). After a median follow-up of 61 months (interquartile range, 44-82), 94 events were observed, including 38 events (37 recurrences and 32 deaths) in the capecitabine group and 56 events (56 recurrences and 40 deaths) in the observation group. The estimated 5-year disease-free survival was 82.8% in the capecitabine group and 73.0% in the observation group (hazard ratio [HR] for risk of recurrence or death, 0.64 [95% CI, 0.42-0.95]; <i>P</i> = .03). In the capecitabine group vs the observation group, the estimated 5-year distant disease-free survival was 85.8% vs 75.8% (HR for risk of distant metastasis or death, 0.60 [95% CI, 0.38-0.92]; <i>P</i> = .02), the estimated 5-year overall survival was 85.5% vs 81.3% (HR for risk of death, 0.75 [95% CI, 0.47-1.19]; <i>P</i> = .22), and the estimated 5-year locoregional recurrence-free survival was 85.0% vs 80.8% (HR for risk of locoregional recurrence or death, 0.72 [95% CI, 0.46-1.13]; <i>P</i> = .15). The most common capecitabine-related adverse event was hand-foot syndrome (45.2%), with 7.7% of patients experiencing a grade 3 event.</span><strong>Conclusions and Relevance</strong> <span>Among women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year, compared with observation, resulted in significantly improved 5-year disease-free survival.</span><strong>Trial Registration</strong> <span>ClinicalTrials.gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT01112826">NCT01112826</a></span></span>
medicine, general & internal